Continuous melt spinning of dried PURASORB PLC 9032 into absorbable monofilament suture has been qualified on single-screw extruders with a 24:1 L/D ratio and a 0.4–1.0 mm single-hole capillary die. The copolymer is vacuum-dried to a residual moisture content below 0.01% by weight before entering the feed throat, because hydrolytic chain scission at melt temperatures above 150°C elevates inherent viscosity loss beyond 0.3 dL/g within 10 min of residence time. The melt spinning zone is maintained between 160°C and 190°C, with a feed-zone set point of 150°C, a compression-zone set point of 165°C, and a metering-zone set point of 180°C; a gear pump after the screw holds melt pressure at 5–10 MPa to reduce diameter pulsation. The as-spun filament is quenched in ambient air at 20–25°C before a two-stage hot draw at 55–70°C and 70–85°C with a total draw ratio of 3:1 to 6:1. The drawn filament is annealed under tension at 60°C for 6 h to reduce free shrinkage and is monitored by online laser micrometer with a diameter tolerance of ±5 µm. The formulation is processed at 100 wt% copolymer, with no plasticiser or lubricant, to avoid reducing molecular weight; a 0.05–0.15 wt% organic dye may be masterbatched only if suture colour coding is required. Orientation increases tensile strength to the range of 250–450 MPa depending on draw ratio, while the caprolactone comonomer retains knot-security-relevant elongation at 30–50%. Compliance for suture-grade fibre includes ISO 13781:2017 for in vitro degradation kinetics, ASTM F1635-16 for hydrolysis testing, ISO 10993-5:2009 for cytotoxicity, and USP Class VI biological reactivity for materials with prolonged patient contact. Terminal product types are monofilament absorbable sutures from USP 6-0 to USP 2-0, used for soft tissue approximation in ophthalmic, dermatological and subcutaneous wound closure where extended tensile strength retention of 2–4 weeks is required.

Why does residual ε-caprolactone depress melt viscosity during injection moulding?

Residual ε-caprolactone comonomer sequences in the copolymer backbone lower the zero-shear viscosity relative to poly(L-lactide) homopolymer of equivalent inherent viscosity, causing the melt to fill thin-wall screw threads at lower injection pressures but also increasing the risk of flash at the parting line when mould-clamp force falls below 40 kN/cm² of projected area. Injection moulding of PURASORB PLC 9032 for fracture fixation pins, interference screws and craniofacial plates uses a reciprocating-screw machine with a 20:1 L/D barrel and a shutoff nozzle, processing at melt temperatures of 165–195°C, mould temperatures of 25–40°C, injection speeds of 20–60 mm/s, hold pressures of 60–100 MPa, and back pressure of 1–3 MPa. The feedstock is vacuum-dried at 80°C for 4–8 h to a moisture content below 0.01%, and the hopper is purged with dry nitrogen at a –40°C dew point to prevent re-absorption. Formulation addition ratio is normally 100 wt% copolymer; where radiographic visibility is required for post-operative device placement, 5–15 wt% barium sulphate or 2–8 wt% hydroxyapatite may be compounded, and these fillers shift the melt viscosity by 10–30% and reduce tensile strength by 10–20% at the upper loading limit. The process includes a post-mould annealing step at 70–90°C for 4–12 h under vacuum to reduce residual stress and increase crystallinity to 20–35%, as measured by differential scanning calorimetry. Compliance evidence for orthopaedic devices includes ISO 13781:2017, ISO 10993-6:2016 for local implantation response, ISO 527-2:2012 for tensile properties, and design controls under ISO 13485:2016. Terminal product types are absorbable interference screws, osteochondral pins, craniofacial fixation plates and suture anchors with programmed load-bearing retention of 8–16 weeks.

Solvent-evaporation microencapsulation of PURASORB PLC 9032 is executed by dissolving the copolymer at 5–15 wt% in dichloromethane, adding the active pharmaceutical ingredient at a polymer-to-drug ratio from 5:1 to 20:1, and emulsifying the organic phase into a 1.0–2.5 wt% aqueous poly(vinyl alcohol) continuous phase using a rotor-stator homogenizer at 5,000–15,000 rpm. The transient solvent is removed by stirring at 300–700 rpm under atmospheric pressure for 2–4 h, followed by vacuum extraction at 50–100 mbar to reduce residual dichloromethane below an analytical limit of 600 ppm as specified in ICH Q3C for Class 2 solvents. Microsphere hardening is driven by polymer precipitation and solvent mass transfer; batch-to-batch variance in mean particle size, typically 20–80 µm, is controlled by vessel geometry, baffle height, and continuous-phase temperature at 15–25°C. Drug migration kinetics in the copolymer matrix follows a biphasic release controlled initially by diffusion through the amorphous caprolactone-rich domains and later by hydrolytic degradation of the lactide-rich crystalline segments. Formulation addition ratio is adjusted to the therapeutic dose; for low-dose peptides the polymer-to-drug ratio may reach 50:1, whereas for high-dose anti-inflammatory drugs it can fall to 5:1 at the risk of burst release above 20% in 24 h. Manufacturing of injectable microspheres is conducted in cleanroom conditions not lower than ISO 14644-1 class 8, with terminal sterilisation validated for the final particle-size distribution. Compliance for injectable microspheres and drug-eluting implants requires ISO 10993-1:2018, ISO 10993-17:2002 for leachables, ICH Q3C residual solvent limits, and in vitro release testing in USP Apparatus 4 flow-through cells at 37°C in phosphate-buffered saline at pH 7.4. Terminal product types include subcutaneous and intramuscular depot microspheres, periodontal drug-eluting inserts, and post-surgical antibiotic-loaded implants with release durations from 2 weeks to 6 months.

Nerve conduit wall leakage and permeability thresholds

Nerve conduit wall leakage and permeability thresholds are governed by the electrospinning solution concentration and the evaporation rate of the chloroform/methanol solvent system. PURASORB PLC 9032 is dissolved at 8–15 wt% in a 70:30 chloroform:methanol mixture, and the solution is metered through a 0.2–0.8 mm needle at 0.5–3.0 mL/h with an applied voltage of 12–25 kV and a collector distance of 12–20 cm. The resulting nonwoven conduit wall has a pore size distribution between 5 and 20 µm and a wall thickness of 200–600 µm, as measured by scanning electron microscopy; leakage is quantified by a hydrostatic pressure drop test with a limit of ≤5% fluid loss over 2 h. The formulation may be processed as 100 wt% copolymer or blended with 5–10 wt% gelatin to improve Schwann-cell adhesion, but the addition of gelatin increases the degradation-related mass loss in the first 14 days and reduces the mechanical suture-retention strength. Production-scale limitations include the need for relative humidity below 40% during electrospinning to prevent phase separation and non-uniform fibre diameter; a coaxial electrospinning configuration is used when a core-shell conduit is required. Published degradation-rate data for this specific copolymer conduit configuration is limited; therefore batch-specific in vitro degradation testing under ISO 13781:2017 is mandatory before design freeze. Compliance standards include ASTM F2150-19 for biomaterial scaffold characterisation, ISO 10993-6:2016 for implantation, ISO 527-3:2018 for film and sheet tensile testing, and ISO 13485:2016 for device manufacturing. Terminal products are resorbable nerve guidance conduits with internal diameters from 2 to 10 mm for peripheral nerve gap repair up to 30 mm.

When PLC 9032 replaces rigid PLLA in craniofacial barrier membranes

When PLC 9032 replaces rigid poly(L-lactide) homopolymer in craniofacial barrier membranes, the caprolactone comonomer lowers the glass transition to between 25°C and 40°C, allowing the membrane to conform around bone graft contours without thermal-assisted shaping. Barrier membranes are produced either by solvent casting of a 10–20 wt% polymer solution in dichloromethane onto a release liner, followed by a phase-inversion precipitation bath at 10–15°C, or by compression molding of pre-dried pellets at 150–170°C under 5–15 MPa for 3–8 min. The resulting membrane is cut into 15–30 mm² sheets with a thickness of 0.1–0.5 mm, and the process is designed to produce an asymmetric pore structure with a dense epithelial-facing layer and a porous bone-facing layer. Kiss-cut rotary knives are specified for die cutting because guillotine cutting at ambient conditions below 20°C has been observed to create edge microcracks in lactide-rich copolymers. Formulation addition ratio is normally 100 wt% copolymer for single-layer membranes; in two-layer designs, the bone-facing layer may be compounded with 10–20 wt% β-tricalcium phosphate to promote osteoconduction, but this increases stiffness and reduces elongation at break to below 10%. Compliance for guided bone and tissue regeneration membranes requires ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-11:2017, ISO 7405:2018 for dental applications, and ASTM D638-14 for tensile testing at 10 mm/min crosshead speed. Terminal product types are resorbable GTR barrier membranes, sinus-lift barrier films and craniofacial guided bone regeneration sheets with barrier function retained for 8–24 weeks.